Hisover-LS Oral Drops contain a combination of Levosalbutamol (0.25 mg), Ambroxol (7.5 mg), and Guaifenesin (12.5 mg), formulated to provide effective relief in respiratory conditions characterized by bronchospasm, mucus hypersecretion, and productive cough. Levosalbutamol, a selective β2-adrenergic receptor agonist, acts as a bronchodilator by relaxing bronchial smooth muscle, thereby improving airflow and alleviating symptoms of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD). Ambroxol serves as a mucolytic agent, facilitating the breakdown and clearance of viscous mucus from the respiratory tract, enhancing mucociliary transport and easing expectoration. Guaifenesin acts as an expectorant, promoting the thinning and loosening of mucus in the airways, which aids in the clearance of phlegm and reduces cough intensity. The synergistic action of these three components makes Hisover-LS Oral Drops suitable for managing acute and chronic respiratory tract infections, bronchitis, and other conditions associated with cough and mucus retention. This formulation is intended for oral administration, with dosage and duration guided by clinical assessment. Use should be monitored in patients with cardiovascular disorders, and it is contraindicated in individuals with hypersensitivity to any component. Consultation with a healthcare professional is recommended prior to use.